The FDA cleared Teva’s Igalmi sublingual film for at-home use, the first at-home approved option for agitation tied to schizophrenia or bipolar disorder.
A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.
Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
WIC participation is estimated at only 44% of eligible Medicaid enrollees in 2023, and just 15% of pregnant Medicaid enrollees. Health plans can help close that gap, but only if their referrals are tracked through enrollment.
In more than 256,000 adults with prediabetes and obesity, GLP-1s were linked to better blood sugar and heart outcomes than metformin, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2026.
Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.